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Abstract A recent publication focused on biomarkers of
future suicidal behaviors identifies several genes expressed
in high-risk states among four samples. We discuss the impli-
cations of this study as well as the current state of research
regarding biomarkers of suicidal behavior.
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Mr. Marks , by mandate of the District of Columbia
Precrime Division , I ’m placing you under arrest for
the future murder of Sarah Marks and Donald Dubin
that was to take place today, April 22 at 0800 hours and
four minutes .
“Minority Report”, Steven Spielberg (2002)
Predicting future behavior is a long-standing goal and a
matter of particular interest for behavioral scientists. The
prediction of suicidal behavior, from minimally harmful to
lethal suicide attempts, is particularly challenging because, thus
far, it depends on the subjective reports of the individual at risk.
However, the elevated expression of certain RNA biomarkers
might help to predict future suicidal behavior according to a
recent paper published in Molecular Psychiatry by Le-
Niculescu and colleagues [1]. Their findings aim to take us
closer to an objective measure of suicide risk. The relevance of
such studies is sustained by other reports showing that suicidal
subjects often do not disclose their suicidal thoughts [2, 3], with
myriad underlying reasons –i.e., hospitalization, fear of stigma,
thwarted plans– for hiding this information [1].
The low base rate of attempted and completed suicide [4],
and the relatively poor performance of models based on a
restricted number of variables [5] are major difficulties in the
prediction of suicidal behavior. To date, clinical factors (notably
depression and alcoholism), previous suicide attempts, and life
events are among the best predictive factors for suicidal behav-
ior [6–8]. Some biological factors have also been closely asso-
ciated with suicide risk, particularly reduced concentrations of
the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA)
in cerebrospinal fluid (CSF) and abnormal results in the dexa-
methasone suppression test (DST) [9]. Given that biomarkers
should be simple to obtain, non-invasive, and inexpensive,
recent research has focused on other putative biomarkers of
suicidal behavior such as reduced cholesterol, omega 3 fatty
acids [10], or brain-derived neurotrophic factor (BDNF) in
serum or plasma [11].
An essential issue is that biomarker studies must use not
only excellent biological approaches but robust phenotypes.
Indeed, given that for complex behaviors such as suicidal
behavior, it is anticipated that only biomarkers of small effect
sizes will be in play, identification is likely to only be attained
when reliable, valid clinical characterization is used. This is a
high bar and one of the reasons why identification of bio-
markers, thus far, has been disappointing.
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Le-Niculescu and colleagues explored blood gene expres-
sion biomarkers for suicidality in four small male cohorts: i)
one discovery cohort of live bipolar subjects (n=9); ii) one
age-matched cohort of suicides from the coroner’s office (n=
9); and iii) two prospective follow-up cohorts with subjects
affected by bipolar disorder (n=42) and psychosis (n=46) [1].
Suicidal behavior in the live subjects was identified using the
suicide-related item of the Hamilton Depression Rating Scale
(HDRS). Suicide was determined by the coroner. Hospitaliza-
tion for suicidal behavior was determined through chart re-
view. Although the higher scores on the HDRS suicide-related
item confound different suicidal behaviors (a score of 3 can
mean “gesture” or pronounced suicidal ideation), the scores
were used to classify individuals as having no suicidal idea-
tion (SI) or high SI. Those with low and high scores were
compared to identify potential biomarkers in the discovery
cohort. Putative relevant biomarkers related to suicidality
were then validated in the cohort of suicides. After correction
for multiple comparisons, four biomarkers differentiated fu-
ture and past hospitalizations with suicidality in the prospec-
tive cohorts of individuals with either bipolar disorder or
psychosis. SAT1 (spermidine/spermine N1–acetyltransferase
1) was identified as the top biomarker comporting with alter-
ations of the polyamine system in brains of suicides described
by Turecki and colleagues [12]. In fact, several genes impli-
cated in polyamine biosynthesis seem to be up-regulated in
the brains of suicides. On the other hand, SAT1 and another
“top” biomarker (CD24 molecule/small cell lung carcinoma
cluster 4 antigen) are related with apoptosis, or programmed
cell death .
Le-Niculescu and colleagues are to be commended for the
use of multi-dimensional approaches in the prediction of suicid-
al behavior. The authors sequentially added data about mood,
anxiety and psychosis to the expression levels of the bio-
markers. They generated a series of receiver-operating charac-
teristic (ROC) curves together with the average area under the
curves (AUC) for increasingly complex models (SAT1; SAT1+
anxiety; SAT1+anxiety+mood; SAT1+anxiety+mood+psy-
chosis) of future hospitalizations due to suicidal behavior. In
this way, they found that the AUC for future hospitalizations
with suicidality increased progressively from 0.640 (with SAT1
alone) to 0.835 (with SAT1, anxiety, mood, and psychosis). In
other words, they enhanced their capability to predict hospital-
izations with suicidality by combining genetic and clinical
factors.
Previous models have achieved better results in classifying
suicide attempters just using the most discriminant items
from four assessment scales and socio-demographic factors
(AUC=0.92) [5]. For a biomarker to be clinically useful, it
must have high sensitivity (>90 %) and specificity (>90 %)
[13]. They should also show strong predictive value [14].
Unfortunately, ROC curves with an AUC<0.75 are not clin-
ically useful [15]. However, the combination of biological
factors with other variables (clinical, psychological) associat-
ed with suicidal behavior may be a good strategy to improve
the predictive capacity of explanatory models.
While acknowledging the value of the study by Le-
Niculescu and colleagues, a number of limitations should be
noted. The most relevant one is the construction of a “predic-
tive” model of suicidal behavior from a small sample of nine
male bipolar individuals with/without suicidal ideation, and
the use of human postmortem brain evidence, a completely
different suicidal endophenotype, to test the model. Even
suicide attempters, a more proximate population than suicide
ideators, share only some of the characteristics of suicide
completers [16]. Before any generalization can be made, their
results need to be replicated in larger, more clearly character-
ized samples. Moreover, the suicidal behavior of live partici-
pants was not well-characterized. The concept of ‘suicidality’,
widely used by the authors, lacks precision and decreases the
validity of their findings [17].
The study by Le-Niculescu and colleagues [1] exempla-
rizes a potential strategy to identify routine blood tests in the
prediction and prevention of suicidal impulses. Unfortunately,
we are still far from this point. Among other pending tasks in
suicidal research, clinicians can refine known endophenotypes
for suicidal behavior, such as impulsive aggression traits or
psychological pain, to facilitate the identification of expressed
genes that are associated with them. Predicting suicidal be-
havior can also be enhanced by selecting the most discrimi-
nant variables [5], using predictors from different do-
mains (clinical, neurobiological and cognitive) [18], and
by applying novel methodological instruments such as
data mining [19]. For the time being, we should remem-
ber that several strategies, such as assuring aggressive
treatment for depression [20] and continuity of care to
prevent relapses [21] may successfully reduce suicide rates,
until such time as we reach the goal of predicting future
suicide events.
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